Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
2012 ◽
Vol 13
(9)
◽
pp. 869-878
◽
Gustavo Ismael
◽
Roberto Hegg
◽
Susanne Muehlbauer
◽
Dominik Heinzmann
◽
Bert Lum
◽
...